Sign in
TerminatedPhase 1

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Key facts

Who runs it
Poseida Therapeutics, Inc.
Where
Baltimore, Boston, Denver, Duarte, Nashville, New Orleans, New York, San Diego, and San Francisco, United StatesSee the 10 sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
40 people enrolled
Started
28 Feb 2020
Ended
30 Sept 2024
Type of study
Interventional, 4 groups
Treatments tested
  • P-PSMA-101 CAR-T cells
  • Rimiducid
Record updated
17 February 2025
Why it stopped
Study closed

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Subjects ≥18 years of age
  • Must have a confirmed diagnosis of mCRPC or SGC
  • Must have measurable disease by RECIST 1.1 or bone only metastases with measurable PSA (≥1 ng/mL) (mCRPC subjects only)
  • Must have progressed by PCWG3 and/or RECIST 1.1 (mCRPC subjects only)
  • Must be willing to practice birth control from screening and for 2 years after the last administration of P-PSMA-101
  • Must have adequate vital organ function within pre-determined parameters
  • Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

Who cannot take part

  • Has received anti-cancer medications (excluding GnRH targeted therapies) within 2 weeks of the time of initiating conditioning chemotherapy
  • Has received immunosuppressive medications (including anti-cancer medications) within 2 weeks of initiating leukapheresis and/or expected to require them while enrolled in the study
  • Has received systemic corticosteroid therapy within 2 weeks of either the required leukapheresis or is expected to require it during the course of the study
  • Has an active second malignancy in addition to mCRPC or SGC, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
  • Has a history of or active autoimmune disease
  • Has a history of significant central nervous system (CNS) disease, such as stroke or epilepsy
  • Has an active systemic (viral, bacterial or fungal) infection
  • Has a history of significant ocular disease
  • Has a history of significant liver disease or active liver disease
  • Has a history of or known predisposition to HLH or MAS
  • Has inadequate venous access and/or contraindications to leukapheresis
  • Has CNS metastases or symptomatic CNS involvement
  • Has liver metastases (<5 lesions and maximum diameter </= 2.5 cm permitted)

Where in United States

  • University of Maryland, BaltimoreBaltimore, United States
  • Dana-Farber Cancer InstituteBoston, United States
  • Massachusetts General HospitalBoston, United States
  • Sarah Cannon Research Institute at HealthONEDenver, United States
  • City of Hope Comprehensive Cancer CenterDuarte, United States
  • Tennessee OncologyNashville, United States
  • Tulane University Hospital and ClinicNew Orleans, United States
  • Memorial Sloan-Kettering Cancer CenterNew York, United States
  • University of California San DiegoSan Diego, United States
  • University of California San FranciscoSan Francisco, United States

About the trial

What the trial wants to find out

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

The 4 groups in the trial

  • P-PSMA-101 CAR-T cells (Single Dose - Part 1a)Treatment being tested

    Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.

    Treatment: P-PSMA-101 CAR-T cells and Rimiducid

  • P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)Treatment being tested

    Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.

    Treatment: P-PSMA-101 CAR-T cells and Rimiducid

  • P-PSMA-101 CAR-T cells (Single Dose - Part 1c)Treatment being tested

    Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.

    Treatment: P-PSMA-101 CAR-T cells and Rimiducid

  • P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)Treatment being tested

    Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.

    Treatment: P-PSMA-101 CAR-T cells and Rimiducid

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Record updated
17 February 2025